[Interactions between the human immunodeficiency virus and hepatitis C virus].
BACKGROUND
Prevalence of hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected subjects is around 9%, varying according to the mode of contamination. Reciprocal interactions between the two viruses have to be evaluated.


BACKGROUND
HCV infection is usually associated with chronic hepatitis and detectable viremia in HIV-infected patients. HIV infection enhances HCV replication, leading to more severe liver lesions and to a more rapid occurrence of cirrhosis. This underlines the need for both early diagnosis and therapy in order to avoid severe evolution of the liver disease.


CONCLUSIONS
Even though the rate of long-term responses to interferon alpha is low, improvement may be expected from combined therapies, especially with combination including ribavirin. The impact of both antiretroviral triple therapy and accompanying immune restoration on natural history and treatment of HCV infection has to be assessed, as the above mentioned consensual conclusions may be modified in a near future.
Pol
S
S
Unité d'hépatologie, hôpital Necker, Paris, France.
Zylberberg
H
H
D019380:Anti-HIV Agents / Q000627:therapeutic use; D000998:Antiviral Agents / Q000627:therapeutic use; D015897:Comorbidity; D018450:Disease Progression; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications* / Q000453:epidemiology / Q000628:therapy / Q000635:transmission / Q000821:virology*; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000453:epidemiology / Q000628:therapy / Q000821:virology*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D015995:Prevalence; D012254:Ribavirin / Q000627:therapeutic use; D014779:Virus Replication
D019380:Anti-HIV Agents; D000998:Antiviral Agents; D016898:Interferon-alpha; D012254:Ribavirin